TY - JOUR
T1 - Murine models of acute neuronopathic Gaucher disease
AU - Berglin-Enquist, Ida
AU - Lobianco, Christophe
AU - Ooka, Andreas
AU - Nilsson, Eva C
AU - Mansson, Jan-Eric
AU - Ehinger, Mats
AU - Richter, Johan
AU - Brady, Roscoe O.
AU - Kirik, Deniz
AU - Karlsson, Stefan
N1 - The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Division of Molecular Medicine and Gene Therapy (013022010), Faculty of Medicine (000022000), Brain Repair and Imaging in Neural Systems (BRAINS) (013212027), Pathology, (Lund) (013030000)
PY - 2007
Y1 - 2007
N2 - Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the glucosidase, beta, acid (GBA) gene that encodes the lysosomal enzyme glucosylceramidase (GCase). GCase deficiency leads to characteristic visceral pathology and, in some patients, lethal neurological manifestations. Here, we report the generation of mouse models with the severe neuronopathic form of GD. To circumvent the lethal skin phenotype observed in several of the previous GCase-deficient animals, we genetically engineered a mouse model with strong reduction in GCase activity in all tissues except the skin. These mice exhibit rapid motor dysfunction associated with severe neurodegeneration and apoptotic cell death within the brain, reminiscent of neuronopathic GD. In addition, we have created a second mouse model, in which GCase deficiency is restricted to neural and glial cell progenitors and progeny. These mice develop similar pathology as the first mouse model, but with a delayed onset and slower disease progression, which indicates that GCase deficiency within microglial cells that are of hematopoietic origin is not the primary determinant of the CNS pathology. These findings also demonstrate that normal microglial cells cannot rescue this neurodegenerative disease. These mouse models have significant implications for the development of therapy for patients with neuronopathic GD.
AB - Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the glucosidase, beta, acid (GBA) gene that encodes the lysosomal enzyme glucosylceramidase (GCase). GCase deficiency leads to characteristic visceral pathology and, in some patients, lethal neurological manifestations. Here, we report the generation of mouse models with the severe neuronopathic form of GD. To circumvent the lethal skin phenotype observed in several of the previous GCase-deficient animals, we genetically engineered a mouse model with strong reduction in GCase activity in all tissues except the skin. These mice exhibit rapid motor dysfunction associated with severe neurodegeneration and apoptotic cell death within the brain, reminiscent of neuronopathic GD. In addition, we have created a second mouse model, in which GCase deficiency is restricted to neural and glial cell progenitors and progeny. These mice develop similar pathology as the first mouse model, but with a delayed onset and slower disease progression, which indicates that GCase deficiency within microglial cells that are of hematopoietic origin is not the primary determinant of the CNS pathology. These findings also demonstrate that normal microglial cells cannot rescue this neurodegenerative disease. These mouse models have significant implications for the development of therapy for patients with neuronopathic GD.
KW - neurodegeneration
KW - lysosomal storage disorder
KW - glucocerebrosidase deficiency
KW - gene therapy
KW - knockout mice
U2 - 10.1073/pnas.0708086104
DO - 10.1073/pnas.0708086104
M3 - Article
SN - 1091-6490
VL - 104
SP - 17483
EP - 17488
JO - Proceedings of the National Academy of Sciences
JF - Proceedings of the National Academy of Sciences
IS - 44
ER -